Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $12.0M | $65.1M | $100M |
| Revenue growth | — | 442.9% | 53.9% |
| Gross profit | $6.31M | $35.9M | $55.5M |
| Gross margin | 52.6% | 55.1% | 55.4% |
| Operating income | -$35.9M | -$45.3M | -$71.7M |
| Operating margin | -298.9% | -69.5% | -71.5% |
| Net income | -$44.1M | -$54.8M | -$73.2M |
| Net margin | -367.6% | -84.1% | -73.0% |
| EPS (diluted) | -$8.31 | -$8.60 | -$1.81 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$32.4M | -$48.3M | -$50.9M |
| Capital expenditures | $402K | $3.40M | $5.30M |
| Free cash flow | -$32.8M | -$51.7M | -$56.2M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $26.6M | $30.4M | $31.6M |
| Total assets | $110M | $150M | $329M |
| Total liabilities | $51.4M | $73.6M | $41.1M |
| Shareholders' equity | -$203M | -$245M | $288M |
| Retained earnings | -$230M | -$297M | -$370M |
| Shares (wtd avg diluted) | 5.30M | 6.37M | 40.5M |
Every figure is extracted from Beta Bionics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.